Search results
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional...
Morningstar· 4 days agoXTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer ...
Is the FDA Pausing More Cancer Trials? It's Hard to Tell
Medscape· 4 days agoIs the FDA Pressing Pause on More Cancer Trials? In October, the US Food and Drug Administration (...
Novartis bags paediatric FDA label expansion for Lutathera
Pharmaceutical Technology via Yahoo Finance· 4 days agoThe US FDA approval decision was based on the data from the open-label Phase II NETTER...in...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 3 days agoBut he cautioned that even as Big Pharma companies buy into the space, they will still have to...
20 Counties with the Highest Cancer Rates in the US
Insider Monkey via Yahoo Finance· 3 days agoIn this article, we will be taking a look at the 20 counties with the highest cancer rates in the US. If you do not want to learn about the global impact...
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 2 days agoFusion (FUSN) is expected to provide updates regarding the developmental program of its lead...
Vitamin D may improve gut health, aid cancer immunotherapy treatments
Medical News Today· 3 days agoPrevious research has looked at using vitamin D in conjunction with cancer immunotherapy....
The Trump trial takes a turn
Politico· 1 day agoCharles...ascended to the throne following the death of his mother Queen Elizabeth II in 2022 — first sought treatment for an enlarged prostate in...
MD Anderson Research Highlights for April 24, 2024
Newswise· 4 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These adva
PSA Detectable After Radical Prostatectomy
Medscape· 5 days agoFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence.